VIBRAMYCIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vibramycin, and when can generic versions of Vibramycin launch?
Vibramycin is a drug marketed by Pfizer and is included in four NDAs.
The generic ingredient in VIBRAMYCIN is doxycycline calcium. There are twenty-eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the doxycycline calcium profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VIBRAMYCIN?
- What are the global sales for VIBRAMYCIN?
- What is Average Wholesale Price for VIBRAMYCIN?
Summary for VIBRAMYCIN
![VIBRAMYCIN drug patent expirations Drug patent expirations by year for VIBRAMYCIN](/p/graph/s/t/VIBRAMYCIN-patent-expirations.png)
![Drug Prices for VIBRAMYCIN](/p/graph/drug-price/VIBRAMYCIN.png)
See drug prices for VIBRAMYCIN
![Drug Sales Revenue Trends for VIBRAMYCIN](/p/graph/drug-sales-revenues/VIBRAMYCIN.png)
Recent Clinical Trials for VIBRAMYCIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Iowa | Phase 4 |
Merck Sharp & Dohme Corp. | Phase 1 |
BioMed Valley Discoveries, Inc | Phase 1 |
Pharmacology for VIBRAMYCIN
Drug Class | Tetracycline-class Drug |
US Patents and Regulatory Information for VIBRAMYCIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | VIBRAMYCIN | doxycycline hyclate | CAPSULE;ORAL | 050007-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Pfizer | VIBRAMYCIN | doxycycline hyclate | INJECTABLE;INJECTION | 050442-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Pfizer | VIBRAMYCIN | doxycycline hyclate | CAPSULE;ORAL | 050007-002 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for VIBRAMYCIN
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Pfizer Limited | Doxirobe | Doxycycline | EMEA/V/C/000044 Treatment of periodontal disease in dogs.Periodontal pocket probing depths >=4 mm are evidence of disease that may be responsive to treatment with the Doxirobe Gel. Use of this product as directed should result in attachment level gains, periodontal pocket depth reductions, local antimicrobial effect and improved gingival health. Noticeable improvements in these parameters should be evident within 2-4 weeks following treatment. The response in individual dogs is dependent on the severity of the condition and rigor of adjunctive therapy. |
Withdrawn | no | no | no | 1999-09-16 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |